MX2023000092A - Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido . - Google Patents
Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido .Info
- Publication number
- MX2023000092A MX2023000092A MX2023000092A MX2023000092A MX2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugate
- relates
- saponin
- pharmaceutical composition
- galnac
- Prior art date
Links
- 239000001397 quillaja saponaria molina bark Substances 0.000 title abstract 5
- 229930182490 saponin Natural products 0.000 title abstract 5
- 150000007949 saponins Chemical class 0.000 title abstract 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000003446 ligand Substances 0.000 abstract 3
- 101150075175 Asgr1 gene Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 102100030755 5-aminolevulinate synthase, nonspecific, mitochondrial Human genes 0.000 abstract 1
- 108700016481 Acute Hepatic Porphyria Proteins 0.000 abstract 1
- 208000003914 Acute hepatic porphyria Diseases 0.000 abstract 1
- 102100022977 Antithrombin-III Human genes 0.000 abstract 1
- 101150102415 Apob gene Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 abstract 1
- 101000843649 Homo sapiens 5-aminolevulinate synthase, nonspecific, mitochondrial Proteins 0.000 abstract 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 abstract 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000004777 Primary Hyperoxaluria Diseases 0.000 abstract 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract 1
- 101150010882 S gene Proteins 0.000 abstract 1
- -1 TTR Proteins 0.000 abstract 1
- 101710146810 Type-1B angiotensin II receptor Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 101150003160 X gene Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005802 health problem Effects 0.000 abstract 1
- 208000009429 hemophilia B Diseases 0.000 abstract 1
- 208000033552 hepatic porphyria Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a un conjugado de saponina que comprende una saponina unida covalentemente a un ligando para ASGPR, comprendiendo el ligando al menos una GalNAc. La invención también se refiere a una combinación farmacéutica que comprende una primera composición farmacéutica que comprende el conjugado de saponina de la invención y una segunda composición farmacéutica que comprende un segundo conjugado de una molécula efectora y un ligando para ASGPR, o un tercer conjugado de una molécula efectora y una molécula de unión para unirse a una molécula de la superficie celular. Además, la invención se refiere a una composición farmacéutica que comprende el conjugado de saponina de la invención y el segundo conjugado o el tercer conjugado. Adicionalmente, la invención se refiere a una combinación farmacéutica o composición farmacéutica de la invención, para su uso como medicamento. La invención también se refiere a una combinación farmacéutica o composición farmacéutica de la invención, para su uso en el tratamiento o la profilaxis de una enfermedad o problema de salud en el que interviene un producto de expresión de los genes: apoB, TTR, PCSK9, ALAS1, AT3, GO, CC5, gen X del VHB, gen S del VHB, AAT y LDH, para su uso en el tratamiento o la profilaxis de un cáncer, una enfermedad infecciosa, una infección vírica, hipercolesterolemia, hiperoxaluria primaria, hemofilia A, hemofilia B, enfermedad hepática relacionada con AAT, porfiria hepática aguda, amiloidosis por TTR, enfermedad mediada por el complemento, infección por hepatitis B o una enfermedad autoinmunitaria. Finalmente, la invención se refiere a un método in vitro o ex vivo para transferir el segundo conjugado o el tercer conjugado de la invención desde el exterior de una célula hacia el interior de dicha célula.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2025899 | 2020-06-24 | ||
| NL2026442 | 2020-09-10 | ||
| PCT/NL2021/050384 WO2021261992A1 (en) | 2020-06-24 | 2021-06-18 | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000092A true MX2023000092A (es) | 2023-04-20 |
Family
ID=85176234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000092A MX2023000092A (es) | 2020-06-24 | 2021-06-18 | Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido . |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230263897A1 (es) |
| EP (1) | EP4171641A1 (es) |
| JP (1) | JP2023532040A (es) |
| KR (1) | KR20230043114A (es) |
| CN (1) | CN116234582A (es) |
| AU (1) | AU2021295358A1 (es) |
| CA (1) | CA3183885A1 (es) |
| IL (1) | IL299357A (es) |
| MX (1) | MX2023000092A (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116655715B (zh) * | 2023-07-27 | 2023-10-20 | 北京炫景瑞医药科技有限公司 | 一种GalNAc衍生物、缀合物、组合物以及它们的用途 |
| CN117563009A (zh) * | 2023-09-01 | 2024-02-20 | 北京悦康科创医药科技股份有限公司 | 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物 |
-
2021
- 2021-06-18 IL IL299357A patent/IL299357A/en unknown
- 2021-06-18 JP JP2022580236A patent/JP2023532040A/ja active Pending
- 2021-06-18 CA CA3183885A patent/CA3183885A1/en active Pending
- 2021-06-18 CN CN202180051254.4A patent/CN116234582A/zh active Pending
- 2021-06-18 AU AU2021295358A patent/AU2021295358A1/en active Pending
- 2021-06-18 US US18/012,769 patent/US20230263897A1/en active Pending
- 2021-06-18 KR KR1020237002660A patent/KR20230043114A/ko active Search and Examination
- 2021-06-18 EP EP21734241.9A patent/EP4171641A1/en active Pending
- 2021-06-18 MX MX2023000092A patent/MX2023000092A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021295358A1 (en) | 2023-02-16 |
| EP4171641A1 (en) | 2023-05-03 |
| IL299357A (en) | 2023-02-01 |
| US20230263897A1 (en) | 2023-08-24 |
| CA3183885A1 (en) | 2021-12-30 |
| JP2023532040A (ja) | 2023-07-26 |
| AU2021295358A9 (en) | 2023-06-29 |
| CN116234582A (zh) | 2023-06-06 |
| KR20230043114A (ko) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000092A (es) | Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido . | |
| ES2847288T3 (es) | Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado | |
| BR112021012222A8 (pt) | Molécula de ligação direcionada à célula melhorada | |
| BR112021026142A2 (pt) | Composto conjugado ligado à cadeia lateral da fórmula, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos | |
| JP2016056209A5 (es) | ||
| US11020408B2 (en) | Polymer composed of repeat units having a biologically active molecule attached thereto via a pH-sensitive bond | |
| JP2018507914A5 (es) | ||
| WO2008083949A3 (en) | Rna-coded antibody | |
| AU2017389094B2 (en) | Aptamer-drug conjugate and use thereof | |
| KR102007278B1 (ko) | 바이러스 진단 및 치료를 위한 인지능 물질 및 이의 제조방법 | |
| JP2009540842A5 (es) | ||
| Kwon et al. | PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation | |
| Dubey et al. | Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy | |
| JP2018521977A5 (es) | ||
| Kamil Zaidan et al. | Exploring the therapeutic potential of lawsone and nanoparticles in cancer and infectious disease management | |
| BRPI0414026A (pt) | composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b | |
| Pincus | Therapeutic potential of anti-HIV immunotoxins | |
| MX2022001066A (es) | Derivados de saponina con ventana terapeutica mejorada. | |
| ZA202304877B (en) | Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof | |
| US20230173092A1 (en) | Antibody-drug conjugates | |
| MX2023000031A (es) | Conjugado de un anticuerpo de dominio unico, una saponina y una molecula efectora, composicion farmaceutica que comprende el mismo, uso terapeutico de dicha composicion farmaceutica. | |
| RU2010140888A (ru) | Улучшенные противораковые терапии | |
| MX2023011031A (es) | Conjugados de amatoxina y anticuerpo especificos de linfocitos b. | |
| CN113164474B (zh) | 维奈托克的水溶性高分子衍生物 | |
| WO2008075706A1 (ja) | 間質性肺炎治療剤 |